M. K. Proteins Ltd
M. K. Proteins Ltd (MKPL) last reported results for the quarter ended Jun 2026, with sales of ₹115 crore and net profit of ₹1.38 crore. The stock last traded at ₹3.94, a market capitalisation of ₹148 crore, on a P/E of 31.5. Over the past 52 weeks the stock has ranged between ₹3.56 and ₹7.4. Figures are as of 6 Oct 2026 and are not real time.
M. K. Proteins Ltd share price and key metrics
- Current price
- ₹3.94
- Market cap
- ₹148 cr
- Stock P/E
- 31.5
- Book value
- ₹2.03
- ROE
- 9.37%
- ROCE
- 10.1%
- Dividend yield
- 0.00%
- 52w high / low
- 7.40/3.56
Metrics as of 6 Oct 2026. Not real time.
Track M. K. Proteins Ltd
Cruxal reads every M. K. Proteins Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
M. K. Proteins Ltd growth and returns
- 10 Years
- 10%
- 5 Years
- 4%
- 3 Years
- 7%
- TTM
- 18%
- 10 Years
- 25%
- 5 Years
- -8%
- 3 Years
- -14%
- TTM
- -50%
- 10 Years
- %
- 5 Years
- 20%
- 3 Years
- -49%
- 1 Year
- -45%
- 10 Years
- 18%
- 5 Years
- 17%
- 3 Years
- 13%
- Last Year
- 9%
M. K. Proteins Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹115 cr, up 0.2% from ₹115 cr a year earlier. Net profit was ₹1.38 cr, down 60.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 33.69 | 39.48 | 137 | 115 | 32.43 | 89.56 | 146 | 115 |
| Expenses | 31.46 | 37.69 | 133 | 109 | 31.39 | 87.19 | 143 | 113 |
| Operating profit | 2.23 | 1.79 | 4.65 | 5.51 | 1.04 | 2.37 | 2.5 | 2.52 |
| OPM % | 6.62% | 4.53% | 3.39% | 4.79% | 3.21% | 2.65% | 1.71% | 2.19% |
| Other income | 0.21 | 0.25 | 0.02 | 0 | 0.12 | 0.02 | 0.12 | 0 |
| Interest | 0.03 | 0.07 | 0.67 | 0.7 | 0.06 | 0.3 | 0.79 | 0.52 |
| Depreciation | 0.07 | 0.11 | 0.09 | 0.1 | 0.11 | 0.12 | 0.11 | 0.15 |
| Profit before tax | 2.34 | 1.86 | 3.91 | 4.71 | 0.99 | 1.97 | 1.72 | 1.85 |
| Tax % | 25.21% | 25.81% | 28.64% | 25.27% | 25.25% | 26.90% | 33.72% | 25.41% |
| Net profit | 1.74 | 1.38 | 2.8 | 3.51 | 0.75 | 1.43 | 1.14 | 1.38 |
| EPS (₹) | 0.05 | 0.04 | 0.07 | 0.09 | 0.02 | 0.04 | 0.03 | 0.04 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
M. K. Proteins Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 165 | 172 | 157 | 194 | 311 | 256 | 315 | 245 | 268 | 383 | 383 |
| Operating profit | 5 | 6 | 5 | 5 | 16 | 16 | 17 | 17 | 13 | 11 | 8 |
| OPM % | 3.0% | 3.2% | 3.2% | 2.5% | 5% | 6% | 5% | 7% | 4.7% | 3.0% | 2.2% |
| Net profit | 1 | 1 | 2 | 2 | 10 | 10 | 11 | 11 | 8 | 7 | 5 |
| EPS (₹) | 0.04 | 0.04 | 0.04 | 0.05 | 0.28 | 0.27 | 0.29 | 0.30 | 0.22 | 0.18 | 0.13 |
TTM is the trailing twelve months to the most recent quarter.
M. K. Proteins Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 3 | 4 | 4 | 4 | 4 | 4 | 13 | 38 | 38 | 38 |
| Reserves | 2 | 11 | 13 | 15 | 25 | 35 | 37 | 24 | 32 | 39 |
| Borrowings | 31 | 33 | 26 | 31 | 25 | 37 | 46 | 20 | 39 | 37 |
| Other liabilities | 12 | 8 | 4 | 7 | 13 | 10 | 8 | 15 | 22 | 18 |
| Total liabilities | 47 | 56 | 47 | 57 | 67 | 86 | 103 | 96 | 131 | 131 |
| Fixed assets | 7 | 6 | 4 | 3 | 2 | 3 | 3 | 3 | 4 | 5 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 7 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 40 | 50 | 43 | 53 | 65 | 83 | 100 | 88 | 120 | 119 |
| Total assets | 47 | 56 | 47 | 57 | 67 | 86 | 103 | 96 | 131 | 131 |
As reported by the company. Total assets equal total liabilities by construction.
M. K. Proteins Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -4 | -12 | 6 | -4 | 6 | -10 | -6 | 32 | -16 | 5 |
| Cash from investing | -1 | -0 | 0 | 0 | -0 | -2 | 0 | -6 | -1 | -2 |
| Cash from financing | 5 | 12 | -7 | 4 | -5 | 12 | 6 | -27 | 18 | -3 |
| Net cash flow | -0 | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | 0 |
| Free cash flow | -5 | -12 | 6 | -4 | 5 | -12 | -6 | 27 | -18 | 4 |
| CFO / operating profit | -65% | -202% | 150% | -77% | 44% | -39% | -6% | 216% | -95% | 70% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
M. K. Proteins Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 12% | 11% | 8% | 8% | 29% | 23% | 20% | 19% | 13% | 10% |
| Debtor days | 10 | 39 | 25 | 18 | 24 | 42 | 19 | 5 | 2 | 2 |
| Inventory days | 83 | 69 | 75 | 79 | 48 | 80 | 91 | 134 | 170 | 114 |
| Days payable | 23 | 12 | 6 | 8 | 10 | 8 | 6 | 19 | 29 | 5 |
| Cash conversion cycle | 70 | 97 | 94 | 89 | 62 | 114 | 104 | 120 | 142 | 110 |
| Working capital days | 20 | 44 | 32 | 36 | 36 | 55 | 57 | 77 | 81 | 62 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
M. K. Proteins Ltd shareholding pattern
Promoters held 74.82% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.83% | 74.82% | 74.82% | 74.82% | 74.82% | 74.82% | 74.82% | 74.82% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 25.17% | 25.18% | 25.17% | 25.18% | 25.17% | 25.18% | 25.17% | 25.18% |
| No. of shareholders | 43,395 | 55,882 | 67,754 | 71,656 | 72,294 | 71,538 | 70,742 | 70,737 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
M. K. Proteins Ltd corporate filings
- M K Proteins Limited appoints Ms. Aritika Garg as Independent Director for a five-year term, effective August 22, 2026Company Updatelow impact
Cruxal's analysis: M K Proteins Limited has announced the appointment of Ms. Aritika Garg (DIN: 11895058) as…
Read the full analysis - Corporate Voting Results Confirm Approval of Key Resolutions at MK Proteins' 14th AGMAGM/EGMmedium impact
Cruxal's analysis: MK Proteins Limited has successfully concluded its 14th AGM held on September 30, 2026…
Read the full analysis - M K Proteins Limited conducts 14th AGM with key resolutions including reappointment of director, related-party transaction approvals, and appointment of independent director, amidst ongoing financial performance updates.AGM/EGMmedium impact
Cruxal's analysis: M K Proteins Limited held its 14th AGM on 30th September 2026 via video conferencing…
Read the full analysis - The Trading Window for transactions in Shares of the Company for all the Employees, Directors, Key Managerial Personnel, Promoters, designated persons and their immediate relatives or any ....Insider Trading / SASTlow impact
- M. K. Proteins Ltd announces 14th Annual General Meeting notice publicationCompany Updatelow impact
Cruxal's analysis: M. K. Proteins Ltd has published the notice for its 14th Annual General Meeting and…
Read the full analysis - M. K. Proteins Ltd issues notice to shareholders for Annual Report accessCompany Updatelow impact
Cruxal's analysis: M. K. Proteins Ltd is sending letters to shareholders whose email addresses are not…
Read the full analysis - M. K. Proteins Ltd schedules 14th Annual General Meeting for September 2026Corp. Actionlow impact
Cruxal's analysis: M. K. Proteins Ltd has announced the closure of its Register of Members and Share…
Read the full analysis - M. K. Proteins Ltd schedules 14th Annual General Meeting for September 30, 2026Corp. Actionlow impact
Cruxal's analysis: M. K. Proteins Limited has announced its 14th Annual General Meeting (AGM) to be held on…
Read the full analysis - M K Proteins Limited Announces 14th AGM and Seeks Shareholder Approval for Material Related Party TransactionsOthersmedium impact
Cruxal's analysis: M K Proteins Limited has scheduled its 14th Annual General Meeting for September 30…
Read the full analysis - M K Proteins Limited Announces 14th Annual General Meeting (AGM) for September 30, 2026, with Proposals for Material Related Party TransactionsAGM/EGMmedium impact
Cruxal's analysis: M K Proteins Limited has scheduled its 14th Annual General Meeting (AGM) for September…
Read the full analysis - M. K. Proteins Limited schedules 14th Annual General Meeting for September 30, 2026Otherslow impact
Cruxal's analysis: M. K. Proteins Limited has announced the scheduling of its 14th Annual General Meeting…
Read the full analysis - M.K. Proteins Limited announces appointment of Independent DirectorOtherslow impact
Cruxal's analysis: M.K. Proteins Limited has appointed Ms. Aritika Garg as an Additional Director…
Read the full analysis - M. K. Proteins Ltd publishes Q1 FY2027 financial results in newspapersCompany Updatelow impact
Cruxal's analysis: M. K. Proteins Ltd has fulfilled its statutory obligation under Regulation 47 of SEBI…
Read the full analysis - M. K. Proteins Limited reports significant YoY decline in Q1 FY27 net profit; Independent Director resignsBoard Meetinghigh impact
Cruxal's analysis: M. K. Proteins Limited reported a sharp decline in financial performance for the quarter…
Read the full analysis - M. K. Proteins Limited announces resignation of Independent Director Laxmi MandalCompany Updatelow impact
Cruxal's analysis: M. K. Proteins Limited has formally notified the stock exchanges regarding the…
Read the full analysis - M. K. Proteins Limited schedules Board Meeting for August 13, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: M. K. Proteins Limited has formally intimated the stock exchanges regarding a board…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.